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ABSTRACT 
Aims To assess whether people who inject drugs (PWID) and who are treated for overdose 
by ambulance services have a greater mortality risk compared with other PWID, and to 
compare mortality risk within potentially critical time-periods (1 week, 1 month, 3 months, 6 
months, 1 year, 5 years) after an overdose attendance with the mortality risk within potentially 
non-critical time periods (time before and/or after critical periods). 
Design  A prospective cohort study. 
 
Setting  Oslo, Norway. 
 
Participants  172 PWID street-recruited in 1997 and followed up until end of 2004. 
 
Measurements  Interview data linked to data from ambulance records, Norwegian 
Correctional Services, Opioid Substitution Treatment records and National Cause of Death 
Registry. Separate Cox regression models (one for each critical time-period) were estimated. 
 Findings  Ambulance services treated 54% of the participants for an overdose during 
follow-up. The mortality rate was 2.8 per 100 person years for those with an overdose and 3.3 
for those without; the adjusted hazard ratio (HR) was 1.3 [95% CI 0.6; 2.6 p=0.482]. 
Mortality risk was greater in all but the shortest critical time-period following ambulance 
attendance than in the non-critical periods. The mortality risk remained significantly elevated 
during critical periods even when adjusted for total time spent in prison and substitution 
treatment. The HR ranged from 9.4 [95% CI 3.5, 25.4] in the month after an overdose to 13.9 
[95% CI 6.4, 30.2] in the five year period. 
Conclusions Mortality risk among PWID is significantly greater in time-periods after an 
overdose attendance than outside these time-periods. 
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INTRODUCTION 
Mortality rates among people who inject drugs (PWID) remain high in developed countries, 
despite extensive knowledge regarding risk factors (1-5). One of these risk factors is injecting 
drug use, which not only increases the risk of death from overdose, but also increases the risk 
of death from cutaneous injection-related infections, venous disease and blood-borne 
infections such as hepatitis and HIV (6-8). Other factors that are well known to be associated 
with higher mortality rates include non-fatal overdoses, older age, being male, having a long 
injecting career and combining opioid injections with alcohol and/or benzodiazepines (9-12). 
In addition, there is an increased risk of fatal overdoses among opioid users in the first month 
after prison release or discharge from abstinence-oriented drug addiction treatment (13-17). It 
is often a combination of these risk factors that increases the mortality risk, and so identifying 
a particularly high-risk subgroup or a high-risk time period is challenging. 
A wide range of interventions has been introduced to reduce risk and harm from injecting 
drug use. Some of these interventions include opioid substitution treatment (OST), needle 
exchange programmes, naloxone distribution and promotion of heroin smoking rather than 
injecting (18-21). However, not all PWID access these interventions and among these 
mortality rates remain high (2, 3, 22). The most common cause of death in this population is 
overdose, but death from suicide, violence, motor vehicle accidents  and hepatitis C-related 
causes are also common (23-26). To reduce premature mortality among this population 
further, it is critical to identify and address those at particularly high mortality risk within this 
high-risk population. 
Slightly more than half of those who experience an overdose are attended by ambulance 
services (11, 27). Thus, ambulance services play an important role in the prevention of 
overdose deaths (11, 28). In some countries the majority of overdose patients are hospitalised 
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by ambulance services (29), while in other countries, the majority are released at the scene 
(30-32). 
Research about those treated by ambulance services for a heroin overdose has found that 
rebound toxicity is rare after naloxone treatment, and it is therefore assumed safe to release 
patients on the scene (33-35). However, one follow up study that recruited participants via 
ambulance records found that those attended for an overdose, had a higher mortality risk 
compared to the general population (36). Three other studies that also recruited their 
participants from ambulance records found an increased mortality risk among those with 
multiple overdose attendances (31, 37, 38). Yet, none of the previous studies have assessed 
the risk of death after an overdose ambulance attendance specifically in street-recruited 
PWID.  
In our study, we examined if those who were treated by ambulance services for an overdose 
comprised a particular high-risk subgroup, within a high-risk PWID population. The first 
objective was to estimate if those treated for an overdose by ambulance services had an 
increased mortality risk compared to those who were not. The second objective was to 
compare mortality risk within potentially critical time-periods (1 week, 1 month, 3 months, 6 
months, 1 year, 5 years) after an overdose attendance with the mortality risk within potentially 
non-critical time periods (time before and/or after critical time-periods), and to adjust for low-
risk time spent in prison and in opioid substitution treatment. If a high-risk subgroup or high-
risk time period was identified, this would suggest that specific interventions to reduce the 
mortality risk should be introduced.  
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METHODS 
Design and study setting 
Our study was a prospective cohort study conducted with street-recruited PWID who were 
approached outside the needle exchange programme (NEP) facility in Oslo in March, June 
and September 1997. The NEP was the only facility that provided clean injecting equipment 
free of charge in Oslo, at the time of the study.  
All individuals in Norway have a unique personal identification number (Social Security 
number). Some participants provided this 11-digit number at inclusion to the study. For those 
who didn’t remember it in full (the first 6 digits constitutes the person’s date of birth), the full 
number was successfully retrieved from the National Population Registry based on the 
combined birth dates and names.  
Interview data were merged with the National Cause of Death Registry from inclusion in 
1997 through to 31.12.2004. The National Cause of Death Registry provided dates and causes 
of death. Causes of death were categorized by Statistics Norway according to the international 
classification system (ICD-9 codes). Ambulance contact dates and reasons for contact 
between 1.1.1997 and 31.12.2004 were obtained from the ambulance services in Oslo. OST 
intake and discharge dates between 1.1.1998 and 31.12.2004 were obtained from the OST 
programme in Oslo. The Norwegian OST programme was established January 1st 1998 (39) 
and so intake dates did not exist prior to this. Incarceration dates and release dates between 
1.1.1997 and 31.12.2004 were obtained from Norwegian Correctional Services.  
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Participants, recruitment and interviews 
Participants were recruited on the street outside the NEP facility after they had collected 
injecting equipment. Researchers and trained research assistants from The Norwegian 
Institute for Alcohol and Drug Research recruited and interviewed the participants. The 
inclusion criterion was for people to have injected at least once in the previous four weeks. 
Each interview took approximately 15 minutes to complete, and was conducted out of earshot 
from others. No monetary incentives were given for participation.  
Data for this study was collected as part of a regular data collection conducted by the National 
Institute for Alcohol and Drug Research, based on anonymous interviews, which started in 
1993. We applied to the Norwegian Data Inspectorate to recruit, for a limited period of time, 
participants to a cohort study. In 1997 we were permitted to include up to 200 respondents. 
The data collection ended in September, and by then 172 PWID had given their consent for 
participation. 
Representativeness 
In 1997, the number of injecting drug users in Oslo was estimated to approximately 4000 
persons (40). The NEP had 103 000 visits that year and distributed 1 553 400 needle and 
syringes (41). Since the NEP was the only facility that provided clean injecting equipment 
free of charge at the time of study inclusion most PWID in Oslo would have been likely to 
visit the facility at some point during the year. Data was collected three times over the year, 
which increased the likelihood of obtaining a representative sample. Furthermore, the gender 
and age distribution of our sample was similar to what was recorded elsewhere for PWID in 
Norway at the time (40). People who inject drugs regularly are more likely to attend the NEP 
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than those who inject less frequently. Consequently our sample probably included a higher 
proportion of the former population than the latter group.  
We have no information about those who refused to participate. However, some who did not 
agree to long-term participation still answered the questionnaire anonymously (n=114), and 
those who agreed to participate long-term did not differ from those who only participated 
anonymously. Both groups had a similar distribution in terms of age, gender, education, age at 
first injection, income, amount of heroin per injection and total amount of heroin consumed 
(42).  
Measures 
The questionnaire sought demographic data such as age, gender, education and current living 
situation and sources of income (work, social benefits, dealing, theft and sex work). The 
questionnaire also included questions about substance use such as heroin, other opioids, 
amphetamine, cocaine, alcohol and cannabis. Respondents were asked about their age at their 
first injection, injection frequency and what substance they most commonly injected; heroin, 
amphetamine, both or other substances. Additionally, we included questions about 
prescription drugs (frequency, type of drug and amount). In 1997, methadone and 
buprenorphine were not available as prescription drugs in Norway. The questionnaire is 
described in more detail elsewhere (42, 43). 
Data linkage 
Norwegian Social Science Data Services staff performed linkage between mortality data from 
The National Cause of Death Registry, Ambulance contact dates, OST intake and discharge 
dates, and incarceration and release dates. The Social Security number was used for matching 
purposes. A de-identified linked data set was then provided for analysis. 
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Variables and data analyses 
All analyses were conducted in Stata 13.1. Student t-tests and proportion tests were used for 
the assessment of differences in baseline characteristics between the two groups “overdose” 
and “no overdose”. 
Crude mortality rates (CMR) per 100 person-years (PY) were calculated by dividing total 
number of deaths during the follow-up period by the total PY contributed by each participant.  
For survival analysis, time-at-risk was the period between inclusion and 31.12.2004. As the 
register data was complete, we did not lose any participants during follow-up. Participants 
were censored at death. The proportionality assumption was satisfied as it was tested using 
Schoenfeld residuals, scaled Schoenfeld residuals and the stphtest in Stata (44). A Cox 
regression survival model could therefore be applied and hazard ratios (HR) and 95% 
confidence intervals (CI) are reported. The Cox regression models were adjusted for gender, 
age at inclusion, length of injecting, total time spent in prison and total time spent in OST. 
Variables in the adjusted models were included because they were known risk factors for 
overdoses and premature mortality among PWID (45-49).  
The second study objective was to examine the mortality risks within potentially critical time-
periods after an overdose treatment by ambulance services (i.e., one month) as compared with 
potentially non-critical time periods (time before and/or after the critical time-periods). Thus, 
this was not a comparison between groups, but between time-periods. The number of persons 
who died within the potentially critical period was divided by exposure time within this 
specific period. The number of persons who died in the potentially non-critical time-period or 
died without any overdose treatment, was divided by exposure time in this specific period, 
including exposure time to death for those who did not have an overdose attendance.  
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A set of dichotomous time dependent indicators was constructed, with values of 1 if the 
participant was observed within the critical time-period following the ambulance attendance 
and 0 if observed within the non-critical time-period. This set of indicators thus captured the 
dichotomy of interest (i.e., specified time-window after the ambulance attendance vs. the non-
critical time period).  Each indicator thus fluctuated between 0 and 1 during the study time 
until death or censoring for those who experienced an overdose attendance and was 0 for 
those who did not experience an attendance during follow-up. Some individuals had more 
than one attendance. A total of 6 indicators was created, one for each critical period (i.e., from 
1 week to 5 years) corresponding to a total of 6 Cox regression models examining mortality 
within that specific period. That is, this indicator was added as an independent factor to the 
Cox regression models, allowing us to compare mortality rates between the critical time-
period and the non-critical time-period: 1-week after ambulance attendance vs. the non-
critical time-period; 1-month after ambulance attendance vs. the non-critical time-period, etc.  
There were no deaths after five years and therefore time-periods after five years were not 
examined. 
Data about imprisonment and ambulance contact dates were available from 1.1.1997, so data 
were left censored (imprisonment and ambulance contacts dates before inclusion date for each 
individual were omitted from the analyses). Incomplete spells for both prison and OST from 
31.12.2004 were right censored.  
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RESULTS 
Description of the sample 
Ambulance services had treated 93 (54%) of the 172 study participants for an overdose at 
least once during the period between the baseline interview in 1997 and 31.12.2004. The 
number of overdose episodes ranged from one to 17, and the median was two. Thirty-three of 
the participants (35%) had experienced one episode, 22 (24%) had two episodes, 20 (22%) 
had three to four episodes, and 18 (19%) had more than four episodes. 
There were no statistically significant differences in baseline characteristics between those 
who had an overdose attendance (n=93) and those who had not (n=79). The proportion of men 
among the overdose group was 71% and 78% among the no overdose group. Although not 
statistically significant, a slightly higher proportion from the overdose group reported sex 
work as an income source (16% vs. 8%). Both groups comprised mainly of persons who 
injected daily or almost daily (90%), and roughly 9 out of 10 injected mainly heroin. The 
overdose group reported a slightly higher mean amount of heroin consumed in the month 
prior to the baseline interview (21.6 g vs. 16.9 g) and a slightly higher proportion reported use 
of prescription drugs, yet none of these differences were statistically significant.  
Insert Table 1 approximately here  
Crude mortality rates and risk of mortality 
The overdose group was followed for a total of 617 PY and by the end of the study, 17 had 
died. Similarly, those with no overdose were followed for a total of 519 PY and 17 died. The 
CMR was 2.8 [95% CI 1.7; 4.4] per 100 PY for those with overdose episodes and 3.3 [95% 
CI 2.0; 5.3] for those without. Using cox regression analysis the unadjusted HR was 0.8 [95% 
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CI 0.4; 1.6 p=0.594] and the adjusted was 1.3 [95% CI 0.6; 2.6 p=0.482]. This means that 
there was not a statistical difference in mortality risk between the two groups.  
In addition, we analysed the association between the number of non-fatal overdoses and 
mortality, but there was no significant association (HR 0.9 95% CI 0.8, 1.1 p=0.410). The 
causes of death in both groups are found in Table 2. The majority in both groups died from 
acute intoxications, mainly due to the use of opioids.  
Insert Table 2 approximately here 
The second study objective was to compare mortality risk within potentially critical time-
periods after an overdose attendance with the mortality risk within potentially non-critical 
time-periods (time before and/or after critical time-periods). Table 3 shows the number of 
deaths, the years at risk, and the CMR for subsequent periods after treatment. In Table 4, the 
unadjusted and adjusted HR is shown for all the examined critical time-periods. Apart from 
the first week after an episode, there was a significantly elevated mortality risk for all the 
other critical periods. For instance, the risk of death was almost ten times higher during the 
month after an overdose attendance compared to the non-critical time-period (HR 9.9 [95% 
CI 3.7, 26.2]).  The unadjusted mortality risk remained elevated, even five years after an 
overdose episode (HR 11.3 [95% CI 5.4, 23.9]). Importantly, the adjusted risk of mortality 
remained significantly elevated also when controlled for gender, age, years of injecting and 
total time spent in prison and OST.  
Insert Table 3 and 4 approximately here 
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DISCUSSION 
Ambulance services had treated 54% of the 172 street-recruited PWID for an overdose at least 
once during follow-up. The median number of overdose attendances among this group was 
two. There were no statistically significant differences in baseline characteristics between 
those with overdose episodes and those without. Most importantly, there was no significant 
difference in mortality risk between the two groups. However, in the comparison of mortality 
risk between potentially critical and non-critical time-periods the risk was greater in all but 
the shortest critical period following overdose treatment. The mortality risk remained 
significantly elevated during critical periods even when adjusted for total time spent in prison 
and substitution treatment. 
Potentially, everyone in the study cohort could be at particularly high risk of mortality. In a 
previous analysis of this data set it was found that the females were 39 times more likely to 
die prematurely compared to women in the general population, while men were 21 times more 
likely compared to men in the general population (43). The majority of the cohort injected 
heroin daily or almost daily, and approximately half of the cohort also used prescription 
drugs, which in combination are known to increase the risk of overdose mortality (9, 45, 50). 
Long-term injecting of drugs is another recognized risk factor for overdose mortality (51-53) 
and the individuals in our cohort had injected on average more than fourteen years at 
inclusion. Furthermore, in the early years of the study OST was only available with limited 
access, which further increased the mortality risk (39). The combination of high-risk 
behaviors, long injecting careers and limited OST availability, suggest that this cohort was 
particularly prone to premature death.  
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Our findings suggest that there is a significantly elevated mortality risk in the time-periods 
after being treated by ambulance services for an overdose, except for in the 1-week period, 
when compared with non-critical time periods. The most common cause of death was 
overdose. Previous studies have found that rebound toxicity and death in the immediate days 
after an overdose attendance, are rare among those who are left on the scene by ambulance 
services after naloxone treatment (12, 28, 33-35). This could suggest that an individual 
survive the first few days after an overdose attendance, but thereafter there is an increased risk 
of death in particular from a new overdose. The risk of death was almost ten times higher 
during the subsequent month after an overdose attendance compared with the non-critical 
time-period and the risk of mortality remained significantly elevated even five years after an 
overdose episode. Similar to the caution that is advised after prison release or after discharge 
from drug-free treatment (13, 15, 54), the same caution should probably be taken when 
someone is treated for an overdose by ambulance services. Specially designed interventions 
such as low threshold OST, and/or referral to other health services, and distribution of take-
home naloxone could be introduced and implemented after an overdose attendance to reduce 
the risk of mortality. 
There have been some changes over the years in the characteristics of the PWID population 
that may mean that our study cohort of PWID differs slightly from PWID populations today. 
Today the PWID population is older and a much higher proportion receives OST (1).  
However, our main findings are still applicable. In Norway, the number of overdose deaths 
was somewhat reduced at the same time as the number of OST patients increased (55, 56). 
However, the number of overdose deaths has remained stable with around 250 to 300 deaths 
yearly since 2002 despite that the number of OST patients nearly tripled between 2002 and 
2011 (56). Importantly, PWID not only in Norway, but also in other countries, still have a 
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substantially increased risk for premature death, and overdoses remain the main cause of 
death in this population (1, 2). Additionally, ambulance services continue to play an important 
role in the treatment of drug overdoses (28-30, 37, 38). Thus, despite some differences in 
characteristics between the study cohort and PWID today, our findings are likely to be 
applicable in most settings where ambulance services treat PWID for overdoses. 
Strengths and limitations 
One of the strengths of our study lies in how we recruited the participants. Street-recruited 
PWID include those who may never enter treatment, nor be incarcerated and thus would have 
been excluded from studies that recruited from treatment centers or prisons. Further, the 
availability of registries based on social security numbers in Norway is rather unique, and this 
strengthens our findings. The registries made it possible to examine ambulance attendances 
and their associations with mortality risk, while controlling for low risk periods such as time 
spent in prison and time spent in OST. Given the extensive use of ambulance services to treat 
overdoses also in other countries the potential implications of our findings may influence 
mortality rates also elsewhere.  
A limitation of our seven-year prospective study among street-recruited PWID, was the small 
sample size. We recognise that a larger study sample would have been more beneficial. In 
addition, it is possible that at the time of the study, some PWID were not using the NEP, and 
so they would have been inadvertently excluded from our cohort. Furthermore, we did not 
have any information about overdose treatments by ambulance services prior to inclusion. It 
could be that those who had no overdose attendance during follow-up, did have overdose 
attendances prior to inclusion. This may be the reason for the lack of difference in mortality 
between the two groups (overdose vs. no overdose). Lastly, reasons for ambulance episodes 
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were not recorded according to a set standard within the ambulance records, and therefore it is 
possible that the number of overdose attendances was underestimated.  
Conclusion 
Our findings suggest that a general investigation of overdose experiences does not uncover 
those at particular high mortality risk within an already high-risk PWID population. Instead, 
our findings show that there was a significantly elevated mortality risk in critical time-periods 
after an individual had been treated by ambulance services for an overdose compared to non-
critical time-periods. Importantly, the risk remained significantly elevated even five years 
after an attendance. The elevated mortality risk in time-periods after an overdose attendance 
suggests that this attendance may be an opportunity to arrange follow-up interventions such as 
direct referral to OST and/or to other health services, and distribution of take-home naloxone. 
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TABLES 
Table 1. Baseline characteristics amongst those treated by ambulance services for an 
overdose and those who were not.  
Characteristics 
Overdose contacts 
n=93 
No contact 
n=79 (100%) 
Test statistics 
Male 71% (66) 78% (62) z=1.1 p=0.260 
Age at interview 31.8 (sd 6.8)c 33.4 (sd 7.4) t=1.3 p=0.097 
>Mandatory years of 
education a 
71% (66) 72% (57) z=0.2 p=0.864 
Work income 14% (13) 16% (13) z=0.5 p=0.651 
Sex work 16% (15) 8% (6) z=-1.7 p=0.088 
Theft 40% (37) 35% (28) z=-0.6 p=0.558 
Dealing 34% (11) 41% (32) z=0.8 p=0.410 
Age at first injection 18.12(5.74) 17.94 (sd 5.0) t=-0.2 p=0.827 
Years of injecting b 13.7 (sd 8.3) 15.4 (sd 8.8) t=1.3 p=0.212 
Daily or almost daily 
injections 
90% (84) 90% (71) z=-0.1 p=0.922 
Heroin most injected 94% (87) 87% (69) z=-1.4 p=0.163 
Mean monthly heroin 
consumption 
21.6 g  (sd 21.3) 16.9 g (sd 16.2) t=-1.5 p=0.131 
Any use of prescription 
drugs 
62% (58)  52% (41) z=-1.4 p=0.166 
 Alcohol ≥2 days a week 
or more 
23% (21) 25% (20) z=0.4 p=0.675 
Cannabis ≥2 days a week 
or more 
35% (33) 41% (32) z=0.7 p=0.498 
a In Norway all children are expected by law to attend school for 10 years.  
Prior to 1997, it was nine years.  
b Age of first injection subtracted from age at inclusion 
Notes: z=Proportions test and t=Student t-test 
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Table 2. Causes of death in the two groups “overdose” and “no overdose” 
Characteristics 
Overdose 
n=93 
No overdose 
n=79 
Acute intoxications   
due to the use of opioids  10 7 
due to use of sedatives or 
hypnotics  
0 1 
Accidental poisoning by and 
exposure to narcotics and 
psychodysleptics [hallucinogens], 
not elsewhere classified  
2 0 
Dependence syndrome due to use of 
opioids and due to multiple drug use and 
use of other psychoactive substances 
1 1 
Suicide  2 1 
Chronic infections (hepatitis C and HIV)  0 2 
Other causes (Traffic accidents, 
drowning, asthma, malignant neoplasm of 
other connective and soft tissue) 
2 5 
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Table 3. Deaths and years at risk by time, since treated for an overdose by ambulance 
services. CMR per 100 PY.  
Time after overdose 
contact 
Deaths Years at risk CMR [95% CI] 
Up to 1 week 1 5 20.0 [1.8, 93.2] 
1- 4 weeks 4 15 26.7 [8.9, 63.4.] 
5-12 weeks 4 29 13.8 [46.1, 32.8] 
13-24 weeks 3 35 8.6 [23.7, 22.9] 
25-52 weeks 1 37 2.7 [2.5, 12.6.] 
1-5 years 4 13 30.8 [10.3, 73.2] 
>5 years 0 14 0 [-0.0, 17.6] 
Total 17 148 11.5 [6.9, 18.0] 
 
  
25 
 
 
Table 4. Risk of death after overdose treated by ambulance services within potentially 
critical time-periods compared to potentially non-critical time-periods 
Potential critical 
time periodsa 
Hazard Ratio (95% CI) 
Unadjusted Adjustedb 
Potential non-critical 
 time periodsc 
1 week      6.4 [0.8, 48.3]           6.0 [0.8,48.1] 1 
1 month 9.9 [3.7, 26.2]** 9.4 [3.5,25.4]** 1 
3 months 8.1 [3.7, 17.8]** 7.7 [3.5,17.2]** 1 
6 months 7.2 [3.5, 15.0]** 7.8 [3.7,16.3]** 1 
1 year 5.8 [2.8, 11.9]** 7.3 [3.5,15.3]** 1 
5 years  11.3 [5.4, 23.9]** 13.9 [6.4,30.2]** 1 
** p < 0.001 
a This was a comparison between potentially critical time-periods and potentially non-critical time periods using 
a separate Cox regression model for each critical period. The number of persons who died within the potentially 
critical period was divided by exposure time within this specific period. The number of persons who died in the 
potentially non-critical period or died without any contact, was divided by exposure time within the non-critical 
period, including exposure time to death for those who did not have an overdose attendance.  
bAdjusted for gender, age, total years of injecting, total years spent in prison and total years spent in OST. 
cThis is time before and/or after potentially critical time-periods. 
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Table XX. Ambulance and Emergency Room attendances in the year before the individual 
died 
 Total 
attendances 
Mean (sd) Median max 
Total  
ambulance attendances* 
n=85 
173 2 .03 (1.88) 1 10 
Overdose 
attendances 
(n=29) 
48 1.66 (0.90) 1 4 
Drug related NOT overdose 
attendanceb 
n=15 
16 1.07 (0.26) 1 2 
Other attendancesc 
n=61 
109 1.79 (1.61) 1 9 
Acute care clinic 
n=125 
503 4.02 (5.1) 2 31 
Antall OD (n=14) 21 1.50 (0.85) 1 4 
Antall drug related (n=41) 74 1.80 (1.50) 1 8 
Other attendances (n=113) 408 3.61 (4.09) 2 34 
NB! The three categories within total ambulance attendances are not exclusive. A person 
could have OD attendance, Drug related NOT OD attenandance and other attendances. 
bDescription of this category 
c Description of this category 
 
Table XX Reasons for ambulance attendance and Emergency room visits Se excel ark i 
google drive. Dette er en mer detaljert tabell. Kutte den ut, kanskje? 
 Ambulance 
attendance (n=85) 
Acute care clinic 
(n=125)* 
Overdose           48 21 
Drug or alcohol related not overdose 16 74 
Psychiatry           11 59 
Other illness           45 101 
Fall, broken limbs, sprains etc 23 138 
Unconscious          23 3 
Pain (stomach, back, chest etc) 7 24 
Brought in by police - 7 
Left before consultation - 19 
Social emergency services - 57 
Total 173 503 
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Table XX Referral after an ambulance attendance  
 Brought to the 
Acute care 
clinic 
Treated at the 
scene 
Hospitalized Total 
Overdose           10 (21%) 28 (58%) 10 (21%) 48 (100%) 
Drug or alcohol related not 
overdose 
4 (25%) 8 (50%) 4 (25%) 16 (100%) 
Other      34 (31%) 19 (18%) 56 (51%) 109 (100%) 
Total 48 (28%) 55 (32%) 70 (40%) 173 (100%) 
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Table 1: Characteristics and circumstances of death among persons with emergency service  
contact compared to persons without ES contact the year prior to fatal overdose in Oslo, 
Norway 2006-2008. N=231 
  Emergency service contact 
 AC  Yes (n=141) No (n=90) 
Age: median years (range)  36 (19-59) 37 (18-57) 
Women (%)  30 (21.3) 21 (23.3) 
Oslo residents (%)  99 (70.2) 59 (65.6) 
Place of death    
Private a (%)  93 (66.0) 62 (68.9) 
Outside/public building (%)  33 (23.4) 23 (25.6) 
Institution (%)  8 (5.7) 4 (4.4) 
Main intoxicant    
Heroin (%)  91 (64.5) 61 (67.8) 
Methadone/buprenorphine (%)  13 (9.2) 12 (13.3) 
Strong pain relieversb (%)  14 (9.9) 6 (6.7) 
Other drugs detected in blood    
Benzodiazepines/hypnoticsc (%)  100 (70.9) 60 (66.7) 
Stimulants d (%)  47 (33.3) 31 (34.4) 
Cannabis (%)  24 (17.0) 17 (18.9) 
Ethanol (%)  27 (19.1%) 18 (20.0%) 
Multiple drugs detected in blood   123 (87.2) 74 (82.2) 
a Includes shelters in addition to private homes 
b Fentanyl, oxycodone, codeine, dextropropoxyphene, tramadol 
c flunitrazepam, diazepam, nitrazepam, alprazolam, oxazepam 
klonazepam, fenazepam, alimemazin, prometazin, zolpidem, zopiclone 
d Cocaine, amphetamine/methamphetamine, ecstasy 
Slettet: (ES)
Formatert: Fransk (Frankrike)
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Table 2: Reasons for emergency service attendance among persons who died from overdose 
in Oslo, Norway 2006-2008.a 
 Reasons for contact 
Total n=141 
n (%)b 
Most recent contact 
Total n=141 
n (%)b 
Somatic diseasec 67 (47.5%) 33 (23.4%) 
Drug-related (drug use/non-fatal 
overdose) reasons 
 
64 (45.4%) 42 (29.8%) 
Injury (assault, fall, fractures, injury 
from car accidents and other bodily 
trauma) 
49 (34.8%) 20 (14.2%) 
Other reasons (Prescription renewal, 
transportation and home visits) 
35 (24.8%) 2 (1.4%) 
Psychiatric/psychosocial reasons 31 (22%) 13 (9.2%) 
Use of social emergency services 22 (15.6%) 13 (9.2%) 
Unconscious 17 (12.1%) 7 (5.0%) 
Left before consultation 10 (7.1%) 1 (0.7%) 
Alcohol-related reasons 7 (5.0%) 1 (0.7%) 
a Please refer to the Methods section for a more detailed description of what contacts reasons 
were included into the different categories 
bPersons may be included into more than one category. 
cThis category included all conditions, diseases and disorders that were somatic and that could 
not be classified elsewhere 
Kommentert [SS1]: Siste kontakt før døden . Kan vi få det 
kalrere? 
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Table 3: Association between emergency service contact and other health and social service contact, N=231. Logistic regression with unadjusted 
and adjusted odds ratios (OR). The group with no emergency contact is reference group. 
 
 
 
 
 
 
aAdjusted for age, gender, p residency and contact with social service/hospital/low threshold service one year prior to death 
 
 
 Emergency service contact OR for emergency service utilization 
 Yes  
(n=141) 
No  
(n=90) 
OR  
(95%CI) Unadjusted 
OR  
(95%CI) Adjusted a  
Social service 78 (55.3%) 32 (35.6%) 2.2 (1.3; 3.9) 2.2 (1.1; 4.3) 
Hospital 72 (51.1%) 25 (27.8%) 2.7 (1.5; 4.8) 2.5 (1.4; 4.6) 
Low threshold services 41 (29.1%) 11 (12.2%) 3.0 (1.4; 6.1) 2.1(1.0; 4.5) 
Drug rehabilitation treatment 36 (25.5%) 14 (15.6%) 1.9 (1.0; 3.7) - 
Opioid maintenance treatment 17 (12.1%) 12 (13.3%) 0.9 (0.4; 2.0) - 
Home care 24 (17.0%) 9 (10.0%) 1.8 (0.8; 4.2) - 
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Figure 1: Frequency of contact with other health and social services other than emergency 
services (ES) among persons who died from overdose in Oslo, Norway 2006-2008, N=231. 
One group (n=141) with ES contact prior to death compared to one group with no ES contact 
(n=90).  
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